Metropolis Healthcare Ltd. has acquired Ambika Pathology Laboratory in Kolhapur, Maharashtra. This acquisition aims to strengthen Metropolis’s leadership in Western Maharashtra and expand its diagnostics network. Ambika Pathology will be developed into a mini regional reference lab, offering over 4,000 advanced and specialty diagnostics tests. This marks Metropolis’s fourth acquisition in the last 10 months.
Strategic Acquisition in Maharashtra
Metropolis Healthcare Limited has completed the acquisition of Dr. R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The acquisition, finalized on September 18, 2025, aims to strengthen Metropolis’s presence and service capabilities in Western Maharashtra. This is the company’s fourth acquisition in the past 10 months.
Ambika Pathology Integration
Ambika Pathology Laboratory, an NABL-accredited facility, has a strong reputation for quality and patient care. It has been acquired through a Business Transfer Agreement and will be integrated into the Metropolis network. This acquisition will contribute to Metropolis’s strategy of building strong regional clusters and expanding diagnostic access across India.
Regional Expansion and Service Enhancement
Metropolis plans to develop Ambika Pathology into a mini regional reference lab, offering over 4,000 advanced and specialty diagnostic tests to patients in Kolhapur and neighboring Tier-2 and Tier-3 towns. Ambika Pathology currently derives nearly 75% of its revenue from B2C walk-in patients and complements Metropolis’s existing network of 19 laboratories across Pune, Kolhapur, and other cities in Western Maharashtra.
Management Commentary
Ms. Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Limited, stated that Maharashtra contributes nearly 40% of the company’s total revenues and that the acquisition strengthens their Western Maharashtra cluster. Mr. Surendran Chemmenkotil, Managing Director, added that integrating Ambika Pathology will provide a strong base to serve patients and clinicians more comprehensively.
Source: BSE
